Neurogene Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Neurogene Inc. (NGNE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$5.61 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-11-14
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $271.00K, a 77.58% decline year-over-year.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was -$1.94M, a 240.13% decline year-over-year.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was -$3.94M.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-09-30 was $1.21M, a 18.80% decline year-over-year.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $3.61M, a 206.26% increase from fiscal 2013.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was $1.18M.
- Neurogene Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was -$224.13K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 123 month |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | $271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.67M derived: sum of 2 quarters · filed 2023-11-14 | -$5.61M 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$5.88M 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | -$3.94M 10-Q · filed 2023-05-08 | |||||||
| 2022-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.59M derived: sum of 2 quarters · filed 2023-11-14 | $1.82M 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $614.00K 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$769.00K 10-Q · filed 2023-05-08 | |||||||
| 2021-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $963.00K derived: sum of 2 quarters · filed 2022-11-14 | $332.00K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$526.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.16M 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | -$631.00K 10-Q · filed 2022-05-09 | |||||||
| 2020-09-30 | $3.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.25M derived: sum of 2 quarters · filed 2021-11-04 | $5.13M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.23M 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $878.00K 10-Q · filed 2021-05-12 | |||||||
| 2019-09-30 | -$36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$3.83M 10-Q · filed 2020-11-09 | ||||||
| 2019-06-30 | -$3.79M 10-Q · filed 2020-08-12 | |||||||
| 2015-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$1.28M derived: sum of 2 quarters · filed 2015-11-10 | -$1.51M 10-Q · filed 2015-11-10 | -$883.54K derived: sum of 4 quarters · filed 2015-11-10 | ||||
| 2015-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$1.23M 10-Q · filed 2015-08-06 | -$600.54K derived: sum of 3 quarters · filed 2015-08-06 | $1.18M derived: sum of 4 quarters · filed 2015-11-10 | ||||
| 2015-03-31 | -$231.00K 10-Q · filed 2015-05-12 | $400.46K derived: sum of 2 quarters · filed 2015-05-12 | $2.18M derived: sum of 3 quarters · filed 2015-11-10 | $4.12M derived: sum of 4 quarters · filed 2015-11-10 | ||||
| 2014-12-31 | $631.46K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $2.41M derived: sum of 2 quarters · filed 2015-11-10 | $4.35M derived: sum of 3 quarters · filed 2015-11-10 | $3.61M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $3.72M derived: sum of 2 quarters · filed 2015-11-10 | $2.98M 10-Q · filed 2015-11-10 | $2.98M 10-Q · filed 2014-11-04 | $2.48M derived: sum of 4 quarters · filed 2015-11-10 | |||
| 2014-06-30 | $1.94M 10-Q · filed 2014-08-11 | $1.21M 10-Q · filed 2015-08-06 | $1.21M 10-Q · filed 2014-08-11 | $708.55K derived: sum of 3 quarters · filed 2015-05-12 | $2.15M derived: sum of 4 quarters · filed 2015-05-12 | |||
| 2014-03-31 | -$735.00K 10-Q · filed 2015-05-12 | -$734.54K 10-Q · filed 2014-05-13 | -$1.23M derived: sum of 2 quarters · filed 2015-05-12 | $208.29K derived: sum of 3 quarters · filed 2015-05-12 | $407.36K derived: sum of 4 quarters · filed 2015-05-12 | $854.21K 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | -$498.26K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $943.29K derived: sum of 2 quarters · filed 2015-03-16 | $1.14M derived: sum of 3 quarters · filed 2015-03-16 | $1.18M 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $1.64M derived: sum of 2 quarters · filed 2014-11-04 | $1.68M 10-Q · filed 2014-11-04 | |||||
| 2013-06-30 | $199.07K 10-Q · filed 2014-08-11 | $236.90K 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | $37.84K 10-Q · filed 2014-05-13 | |||||||
| 2012-12-31 | -$224.13K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |